JANICE NICOLE CORMIER to Cost-Benefit Analysis
This is a "connection" page, showing publications JANICE NICOLE CORMIER has written about Cost-Benefit Analysis.
Connection Strength
0.305
-
Value-based health care: a surgical oncologist's perspective. Surg Oncol Clin N Am. 2012 Jul; 21(3):497-506, x.
Score: 0.076
-
Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.
Score: 0.057
-
Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007 Jun 10; 25(17):2442-8.
Score: 0.053
-
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? Cancer. 2006 Nov 15; 107(10):2328-36.
Score: 0.051
-
Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value Health. 2015 Dec; 18(8):1070-8.
Score: 0.024
-
Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct; 32(10):1005-13.
Score: 0.022
-
Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014 Jan-Feb; 17(1):34-42.
Score: 0.021